Get started
Work

A BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity

Year: 2025
Type: article
DOI: 10.1038/s41564-024-01895-4
Authors: Alexander A. Smith, Hongwei Su, Joshua Wallach, Yao Liu, Pauline Maiello, H. Jacob Borish, Caylin Winchell, Andrew W. Simonson, Philana Ling Lin, Mark Rodgers, Daniel Fillmore, Jennifer Sakal, Kan Lin, Valerie Vinette, Dirk Schnappinger, Sabine Ehrt, JoAnne L. Flynn
Language: English
Field: Medicine
Open Access status: green
Funders: U.S. Department of Health and Human Services, Harvard University, Leidos, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases
Awards: G1196564293, G1619536081, G2833012269, G2872085235, G3917680530, Pittsburgh HIV Mentored Training for Investigation of Co-morbidities and Cure (HIV MeTrICC), G5358086572, Development of a Self Inactivating, Highly Effective TB Vaccine, G5936413717, G5944368067, G6012682559, G6346658092, G7578466963, Autoimmunity and Immunopathology Training Program, G8361261777, G8422249695, G8796308957, G8857056862, Ghana-SPARCO: Ghana Sickle Pan-African Research Consortium, Immunology of Infections Disease Renewal 2023
OpenAlex ID: W4406231829
FWCI: 10.44
Cites: 33
Cited by: 19
Related to: 10